Biological and functional characteristics of a novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL-14959, in vitro and in vivo

Diabetes, Obesity and Metabolism

Volumn 14, Issue 6, 2012, Pages 511-517

  Nakamura, T ^a   Tanimoto, H ^a   Mizuno, Y ^b   Tsubamoto, Y ^a   Noda, H ^a  

^a Sanwa Kagaku Kenkyusho   (Japan)

^b Sanwa Kagaku Kenkyusho   (Japan)

Author keywords

GIP; GIP receptor antagonist; Glucose homeostasis; Insulin secretion; Lipase activity; Lipid homeostasis

Indexed keywords

CYCLIC AMP; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; RECEPTOR; RECEPTOR BLOCKING AGENT; SKL 14959; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CHO CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INTRAPERITONEAL GLUCOSE TOLERANCE TEST; LIPID METABOLISM; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84862804002     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01555.x     Document Type: Article

References (42)

1. Brown JC, Pederson RA, Jorpes E, Mutt V. Preparation of highly active enterogastrone. Can J Physiol Pharmacol 1969; 47: 113-114.
2. Brown JC, Dryburgh JR. Further purification of a polypeptide demonstrating enterogastrone activity. J Physiol 1970; 209: 57-64.
3. Creutzfeldt W. The incretin concept today. Diabetologia 1979; 16: 75-85.
4. Takeda J, Seino Y, Tanaka K et al. Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proc Natl Acad Sci U S A 1987; 84: 7005-7008.
5. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the seretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993; 133: 2861-2870.
6. Yip RG, Boyman MO, Kieffer TJ, Wolfe MM. Functional GIP receptors are present on adipocyte. Endocrinology 1998; 139: 4004-4007.
7. Yamada Y, Hayami T, Nakamura K, Kaisaki P, Someya Y. Human gastric inhibitory polypeptide receptor cloning of the gene (GIPR) and cDNA. Genomics 1995; 29: 773-776.
8. Moens K, Heimberg H, Flamez D, Huypens P, Quartier E. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 1996; 45: 257-261.
9. Wheeler MB, Gelling RW, Mcintosh CH, Georgiou J, Brown JC. Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties. Endocrinology 1995; 136: 4629-4639.
10. Eckel RH, Fujimoto WY, Brunzell JD. Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocyte. Diabetes 1979; 28: 1141-1142.
11. Knapper JM, Puddicombe SM, Morgan LM, Fletcher JM. Investigations into the actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1(7-36) amide on lipoprotein lipase activity in explants of rat adipose tissue. Nutrition 1995; 125: 183-188.
12. Kim SJ, Nian C, Mclntosh CH. Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. J Biol Chem 2007; 282: 8557-8567.
13. Hauner H, Glatting G, Kaminska D, Pfeiffer EF. Effects of gastric inhibitory polypeptide on glucose and lipids metabolism of isolated rat adipocytes. Ann Nutr Metab 1988; 32: 282-288.
14. Getty-Kaushik L, Song DH, Boylan MO, Corkey BE, Micheal Wolfe M. Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification. Obesity 2006; 14: 1124-1130.
15. Beck B, Max JP. Hypersensitivity of adipose tissue to gastric inhibitory polypeptide action in the obese zucker rat. Cell Mol Biol 1987; 33: 555-562.
16. Oben J, Morgan L, Fletcher J, Marks V. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 1991; 130: 267-272.
17. Wasada T, McCorkle K, Harris V, Kawai K, Howard B. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dog. J Clin Invest 1981; 68: 1106-1107.
18. Ebert R, Nauck M, Creutzfeldt W. Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats. Horm Metab Res 1991; 23: 517-521.
19. Ebert R, Frerichs H, Creutzfeldt W. Impaired feedback control of fat induced gastric inhibitory polypeptide (GIP) secretion by insulin in obesity and glucose intolerance. Eur J Clin Invest 1979; 9: 129-135.
20. Creutzfeldt W, Ebert R, Willims B, Frerichs H, Brown JC. Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels. Diabetologia 1979; 14: 15-24.
21. Salera M, Giacomoni P, Pironi L, Cornia G, Capelli M, Marini A. Gastric inhibitory polypeptide release after oral glucose: Relationship to glucose intolerance, diabetes mellitus, and obesity. J Clin Endocrinol Metab 1982; 55: 329-336.
22. Elahi D, Andersen DK, Muller DC, Tobin JD, Brown JC, Andres R. The enteric enhancement of glucose-stimulated insulin release: The role of GIP in aging, obesity, and non-insulin-dependent diabetes mellitus. Diabetes 1984; 33: 950-957.
23. Flatt PR, Bailey CJ, Kwasowski P, Swanston-Flatt SK, Marks V. Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice. Diabetes 1983; 32: 433-435.
24. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-742.
25. Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 2007; 50: 1752-1762.
26. Irwin N, McClean PL, O'Harte FP, Gault VA, Harriott P, Flatt PR. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia 2007; 50: 1532-1540.
27. Irwin N, Flatt PR. Evidence for benefical effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia 2009; 52: 1724-1731.
28. Gault VA, Parker JC, Harriott P, Flatt PR, O'Harte FP. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol 2002; 175: 525-533.
29. Tseng CC, Kieffer TJ, Jarboe LA, Usdin TB, Michael Wolfe M. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). J Clin Invest 1996; 98: 2440-2445.
30. Gault VA, O'Harte PM, Harriott P, Flatt PR. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Commun 2002; 290: 1420-1426.
31. Kubota K, Yamada Y, Hayami T, Yasuda K, Someya Y. Identification of two missense mutations in the GIP receptor gene: a functional study and association analysis with NIDDM: no evidence of association with Japanese NIDDM subjects. Diabetes 1996; 45: 1701-1705.
32. Adelhorst K, Hedegaard BB, Kundsen LB, Lirk O. Structure-activity studies of glucagon-like peptide-1. J Biol Chem 1994; 269: 6275-6278.
33. Cascieri MA, Koch GE, Ber E, Sadowski SJ, Louizides D. Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. J Biol Chem 1999; 274: 8694-8697.
34. Kawai K, Yokota C, Ohashi S, Watanabe Y, Yamashita K. Evidence that glucagon stimulates insulin secretion through its own receptor in rats. Diabetologia 1995; 38: 274-276.
35. Miyawaki K, Yamada Y, Yano H, Seino Y. Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci U S A 1999; 96: 14843-14847.
36. Zhou H, Yamada Y, Tsukiyama K, Miyawaki K. Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action. Biochem Biophys Res Commun 2005; 335: 937-942.
37. Grigilo S, Sultan F, Lagrange D. Role of hepatic lipase in the catabolism of chylomicron remnants in the rat. Diabete Metab 1992; 18: 150-155.
38. Kim GJ, Antonios Z, Knapper JME, Helen MR. Differences in glucose-dependent insulinotropic polypeptide hormone and hepatic lipase in subjects of southern and northern Europe: implications for postprandial lipemia. Am J Clin Nutr 2000; 71: 13-20.
39. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157.
40. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous systemic human gastric inhibitory polypeptide and GLP-1(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentration. J Clin Endocrinol Metab 1993; 76: 912-917.
41. Gault VA, O'Harte FPM, Harriott P. Effects of the novel (Pro3)GIP antagonist and exendin(9-39) amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia 2003; 46: 222-230.
42. Meier JJ, Nauck MA. GIP as a potential therapeutic agent? Horm Metab Res 2004; 36: 859-866.